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Abstract
c-Hydroxybutyric acid (GHB) is an endogenous compound and a drug used clinically to treat the symptoms of narcolepsy.
GHB is known to be an agonist of GABAB receptors with millimolar affinity, but also binds with much higher affinity to
another site, known as the GHB receptor. While a body of evidence has shown that GHB does not bind to GABAA receptors
widely, recent evidence has suggested that the GHB receptor is in fact on extrasynaptic a4b1d GABAA receptors, where GHB
acts as an agonist with an EC50 of 140 nM. We investigated three neuronal cell types that express a tonic GABAA receptor
current mediated by extrasynaptic receptors: ventrobasal (VB) thalamic neurons, dentate gyrus granule cells and striatal
medium spiny neurons. Using whole-cell voltage clamp in brain slices, we found no evidence that GHB (10 mM) induced any
GABAA receptor mediated current in these cell types, nor that it modulated inhibitory synaptic currents. Furthermore, a high
concentration of GHB (3 mM) was able to produce a GABAB receptor mediated current, but did not induce any other
currents. These results suggest either that GHB is not a high affinity agonist at native a4b1d receptors, or that these
receptors do not exist in classical areas associated with extrasynaptic currents.
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Introduction
c-Hydroxybutyric acid (GHB) is a naturally occurring GABA
metabolite, a recreational drug and is used therapeutically as a
treatment for the symptoms of narcolepsy and to treat alcohol
dependence and withdrawal [1]. GHB causes dose-dependent
sedation, ataxia and hypothermia, however, the molecular
mechanism of action is unclear. GHB binds with low micromolar
affinity to GABAB receptors and many of its effects can be directly
ascribed to activation of these receptors. Specifically, pretreatment
with specific GABAB receptor antagonists prevents GHB-induced
hypothermia, ataxia and sedation, effects which GABAB(1)
2/2
mice are also resistant to [2–5]. In vitro, GHB has been shown to
hyperpolarize neurons by opening potassium channels and
decrease neurotransmitter release, by inhibiting calcium channels,
again an effect that is generally reported to be mediated
specifically by GABAB receptors [6–8]. GHB also binds to at
least one other receptor apart from the GABAB receptor, the so-
called ‘‘GHB receptors’’. GHB binds to this site with nano- to
micromolar affinity and is antagonised by the compound NCS-
382. In apparent disagreement with the work already cited, NCS-
382 has been demonstrated to block GHB-induced hypolocomo-
tion and ataxia [9][though see 2]. Similarly, the purported specific
GHB receptor agonist c-hydroxyvaleric acid mimics some of the
effects of GHB (e.g. ataxia, sedation) without binding to the
GABAB receptor [10]. Likewise, one report shows that GHB
reduces GABA release via a presynaptic mechanism that is
blocked by NCS-382 [11]. While a high affinity target of GHB has
been cloned, it is not sensitive to NCS-382 [12]. Therefore, the
exact molecular nature of the GHB receptor is unclear.
Several studies have shown that GHB does not directly affect
the function of cortical synaptic GABAA receptors
[7,13,14][though see 15]. Likewise, there are several reports
showing that neither GHB nor NCS-382 affect the binding of
classical GABAA receptor ligands [16–18][though see 19].
However, a recent study by Absalom et al., (2012) concluded
that GHB binds to extrasynaptic GABAA receptors [20].
Extrasynaptic GABAA receptors are classically high-affinity
a4bd or a6bd receptors expressed in the perisynaptic or
extrasynaptic space, which mediate a tonic inhibitory current
[21]. These receptors are found in the highest density in dentate
gyrus granule cells, the ventrobasal (VB) thalamic neurons and
cerebellar granule cells, but they can also be found in striatal
medium spiny neurons and to a lesser extent in neocortical
pyramidal cells [22]. Using a Xenopus oocytes expression
system, Absalom et al., (2012) demonstrated that GHB was a
high potency partial agonist of a4b1d GABAA receptors
[EC50= 140 nM], but only activated a4b2/3d GABAA recep-
tors in the millimolar range. Furthermore, they showed that this
effect was absolutely dependent on a4 and d subunits and was
blocked by classical antagonists of the GABAA receptor. In
native tissue, they went on to show that the Bmax of [3H]NCS-
382 binding was significantly reduced in a4 subunit knockout
mice (though not in d subunit knock outs).
Therefore, we sought to investigate where GHB was a
functional agonist of extrasynaptic a4bd receptors in the rat
brain. We elected to examine this in VB thalamocortical neurons,
dentate gyrus granule cells and striatal medium spiny neurons, as
all these cell types express a measurable tonic current mediated by
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a4bd neurons and are believed to express the b1 subunit (though
generally in lower abundance than b2 or b3) [22–25].
Materials and Methods
All experiments were carried out in accordance with the United
Kingdom Animals (Scientific Procedures) Act 1986 and with local
ethical committee (Cardiff University Research Ethics Committee)
approval. All efforts were made to minimize animal suffering and
keep the animal numbers to a minimum. Animals used were
Wistar rats of either sex (postnatal days 20–30), feed ad libitum
and kept on a 12 h light/dark cycle.
Animals were anesthetised with 5% isoflurane/95% O2 and
rapidly decapitated. The brain was dissected out into 4uC sucrose
artificial cerebrospinal fluid (aCSF) bubbled with 95% O2/5%
CO2 of the following composition (in mM) 85 NaCl, 60 sucrose
2.5 KCl, 25 NaHCO3, 1.25 NaH2PO4, 2 MgCl2, 1 CaCl2, 25 D-
glucose, 3 kynurenic acid. The brain was cut using a vibrotome
(Microm HM 650 V, Thermo Fisher Scientific) into 300 mm
horizontal sections of the VB thalamus and dentate gyrus, or
coronal sections for the dorsal striatum. Slices were transferred to a
holding chamber filled with sucrose aCSF where they were
maintained at 35uC for half an hour before being allowed to cool
to room temperature. At that time, the sucrose aCSF was slowly
exchanged with aCSF of the following composition (in mM)
125 NaCl, 2.5 KCl, 25 NaHCO3, 1.25 NaH2PO4, 2 MgCl2,
1 CaCl2, 25 D-glucose. After a further half hour, slices were
transferred to the recording chamber as needed, and kept for a
maximum of 8 hours.
Brain slices were perfused with aCSF of the following
composition at 2–3 mL min21 (in mM) 125 NaCl, 2.5 KCl,
25 NaHCO3, 1.25 NaH2PO4, 1 MgCl2, 2 CaCl2, 25 D-glucose
which was maintained at ,34uC (TC2-BIP, Cell Microcontrols,
USA). CNQX (10 mM) and D-AP5 (25 mM) were added to the
recording solution at all times to block glutamatergic currents.
Neurons were visualized using either a Nikon Eclipse E600FN
(Tokyo, Japan) or Olympus BX51 (Tokyo, Japan) microscope
equipped with a 40 or 606 immersion lens and a video camera
(Hamamatsu, Hamamatsu City, Japan). To investigate whether
GHB (100 mM) or THIP (1 mM) enhanced the tonic current or
altered synaptic events whole-cell patch-clamp recordings were
made from neurons held at –70 mV using pipettes (resistance, 2–
4 MV) containing the following (in mM): 130 CsCl, 4 Mg-ATP,
0.3 Na-GTP, 10 Na-HEPES, and 0.1 EGTA, pH 7.25 (osmolal-
ity, ,295 mOsm). When GHB (3 mM) was used, to allow the
GABAB receptor mediated effects to be recorded, the pipettes
were filled with the following (in mM): 130 K-MeSO4, 5 NaCl,
4 Mg-ATP, 0.3 Na-GTP, 10 Na-HEPES, and 0.1 EGTA,
pH 7.25 (osmolality, ,295 mOsm) at the cells were held at
250 mV. Experimental data was filtered at 3–6 kHz, digitized at
20 kHz (Digidata 1322A; Axon Instruments) and acquired using
pClamp 10 software (Axon Instruments). Series resistance (Rs) was
measured at the beginning of the recording, and if it was over
20 MV the experiment was ended. Rs was measured again at the
end of the recording and if it had changed by more than 20% since
the experiment had begun, the data was discarded. For VB
neurons the mean initial Rs was 14.460.8 MV and this had
increased to 15.760.8 MV (n = 22) by the end of the recording
session. For dentate gyrus granule cells the mean Rs value was
9.561 MV which increased to 10.361.2 MV (n = 17) by the end
of the experiment. For striatal neurons the initial Rs was
10.760.5 MV and by the end of the experiment this was
11.460.7 MV (n = 23). Nucleated patches were pulled using
standard methods and the CsCl based pipette solution described
above and held at 270 mV [26]. Nucleated patches were
acceptable if they were roughly spherical, had a whole-cell
capacitance of ,3 pF and an input resistance of .500 MV.
Drugs were puff applied onto patches for 2 seconds every 20
seconds using a custom built TTL-driven picospritzer system from
a pipette with a 5–10 mm tip held ,50 mm from the patch. Drugs
were dissolved in standard aCSF. To allow representative images
of cells to be imaged and classical membrane properties to be
recorded, occasionally 25 mM Alexa Fluor 594 was added to K-
MeSO4 pipette solution. Two-photon laser-scanning microscopy
(2P-LSM) was performed using a Prairie Ultima (Prairie Tech-
nologies) microscope powered by a titanium:sapphire pulsed laser
(Chameleon Ultra II; Coherent) tuned to l=810 nm. Maximum
intensity projections were constructed from Z series of images
taken with 1 mm focal steps using MetaMorph software (Molecular
Devices) and ImageJ (NIH).
GHB was purchased from Sigma-Aldrich. All compounds used
for aCSF and pipette solution were purchased from Fischer
Scientific or Sigma-Aldrich. CNQX, D-AP5, CGP 55845,
Tetrodotoxin (TTX) and 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyri-
din-3-ol (THIP) were purchased from Tocris.
To measure the holding current in a way that was not affected
by spontaneous IPSCs, an all points sample of the data was
collected every second, and the mode of this sample was used to
define the holding current. To measure the effect of a drug on the
holding current an average of 10 seconds of these samples just
prior to the application of the drug was used to create the control
value, and 10 seconds of samples at the end of drug application
was used to create the drug value. Miniature IPSCs were detected
using the template function of Axograph X (Axograph Scientific).
Drug induced changes in holding current and drug-puff induced
currents were tested with paired t-tests and one sample t-tests
respectively, using Graphpad Prism. mIPSC amplitude distribu-
tions were tested with Kolmogorov-Smirnov tests using pClamp.
P,0.05 was taken as significant.
Results
To investigate whether GHB activated a4bd receptors we
first performed whole cell voltage clamp recordings from VB
thalamic neurons using a CsCl based internal solution. Under
these conditions ([Cli] = 130 mM, [Clo] = 133.5 mM,
Vhold =270 mV), if GHB activated any significant population
of GABAA receptors we would expect to see an inward current.
We applied GHB at 10 mM because this is approximately 100
times the EC50 concentration for activating a4b1d receptors but
approximately 100 times less than its EC50 for activating
GABAB receptors or a4b2/3d receptors [20,27]. GHB at this
concentration had no effect on the holding current (control:
2239627 pA, GHB: 2242626 pA; n= 7, P=0.75; Fig. 1A1–
2). To confirm the validity of our assay, we applied the d
selective agonist THIP (1 mM) [28] and this produced a
significant inward current (n = 6, P=0.007; Fig. 1A3). We
repeated this experiment in dentate gyrus granule cells and
again saw that GHB (10 mM) had no effect on the holding
current (control: 2129615 pA, GHB 2129613 pA; n= 6,
P=0.91; Fig. 1B1–2). Again, THIP induced a significant
inward current (n = 7, P=0.01). Finally, we patched striatal
cells. With our CsCl based patch solutions, we could not
confirm whether all cells we recorded from were medium spiny
neurons, however, we targeted neurons with small somata
(diameter ,15 mm) making it unlikely that we accidentally
recorded from cholinergic interneurons. Likewise, the fact that
medium spiny neurons make up approximately 95% of all
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striatal cells, makes it further unlikely that we recorded from
other cell types [29]. However, again, GHB (10 mM) had no
effect on the holding current (control: 2293623 pA, GHB:
2294622 pA; P= 0.7, n= 9; Fig. 1C1–2), while THIP
produced a significant inward current (n = 10, P,0.0001).
These results seem to indicated that GHB (10 mM) does not
modulate extrasynaptic receptors in VB thalamic neurons, dentate
gyrus granule cells and striatal medium spiny neurons. However,
because the exact subunit composition of synaptic and extra-
synaptic receptors is unclear (especially when it comes to which b
subunits are involved), and hence there is a chance that GHB
sensitive GABAA receptors are expressed synaptically, we sought
to confirm whether GHB modulates synaptic GABAA receptor
mediated currents. Miniature IPSCs (mIPSCs) were isolated with
TTX (500 nM). In the VB thalamus, mIPSCs had a mean
amplitude of 4064 pA and a mean decay time constant of
4.960.4 ms, however GHB (10 mM) had no effect on these
parameters (3664 pA, 4.760.4 ms; n= 9, P=0.5, P=0.4 respec-
tively; Fig. 2A). Furthermore, GHB (10 mM) had no effect on the
distribution of mIPSC amplitude (P=0.6; Fig. 2A3). Similarly,
GHB (10 mM) had no effect on mIPSCs recorded in dentate gyrus
granule cells (control: 4262 pA, 7.460.1; GHB: 4162 pA,
7.560.1 ms; n = 6, P=0.5, P=0.6 respectively; Fig. 2B). Finally,
GHB (10 mM) had no effect on mIPSCs recording from striatal
medium spiny neurons (control: 3964 pA, 9.660.2 ms; GHB:
3964 pA, 9.660.3 ms; n= 11, P=0.8 P=0.7 respectively;
Fig. 2C).
Endogenous GHB is found in the CSF at approximately
100 nM (and .1 mM in bulk tissue), and the concentration is
reported to increase after death [30,31], therefore it seems possible
that endogenous GHB is saturating any high affinity GHB
receptors in our brain slices. Therefore, we sought to avoid this
Figure 1. GHB has no effect on the holding current of voltage clamped neurons. A1, Mean holding current over time in response to the
application of GHB in VB thalamic neurons (n = 6). Grey area shows SEM. Left inset, representative image of a VB neuron. Scale bar 50 mm. Right inset,
voltage response of a representative VB neuron to current injection. Scale bar 20 mV 200 ms. A2, Group results showing the mean holding current
before and after GHB. A3, The d-selective GABAA agonist THIP induced a significant inward current (control: 2221633 pA, THIP: 2508653 pA, n= 6,
P= 0.0007). B1, Mean holding current over time in response to the application of GHB in dentate gyrus (DG) granule cell (n = 6). Grey area shows SEM.
Left inset, representative image of a dentate gyrus granule cell. Scale bar 50 mm. Right inset, voltage response of a representative dentate gyrus
granule cell to current injection. Scale bar 20 mV 200 ms. B2, Group results showing the mean holding current before and after GHB. B3, THIP
induced a significant inward current (control: 2131610 pA THIP: 2211622 pA, n = 7, P= 0.01). C1, Mean holding current over time in response to
the application of GHB in striatal medium spiny neurons (MSN) (n = 9). Grey area shows SEM. Left inset, representative image of a medium spiny
neuron. Scale bar 50 mm. Right inset, voltage response of a representative medium spiny neuron to current injection. Scale bar 20 mV 200 ms. C2,
Group results showing the mean holding current before and after GHB. C3, THIP induced a significant inward current (control: 2314626 pA THIP:
2457626 pA, n = 10, P,0.0001).
doi:10.1371/journal.pone.0079062.g001
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problem by puff applying GHB onto nucleated patches drawn
above the surface of the slice (.200 mm). We avoided using
dissociated cell culture, due to the risk of ectopic expression of ion
channels not expressed in native tissue. Likewise, we did not use
outside-out patches, as that would mean we could only sample a
small area of membrane, potentially missing a receptor expressed
at low density. Unfortunately, nucleated patches only allow us to
sample the somatic membrane. As it is known that the a4bd
expressed by dentate gyrus granule cells are restricted to the distal
dendrites, we excluded using these cells for this experiment [32].
Puff application of THIP (1 mM) demonstrated a small bicuculline-
sensitive current in both thalamocortical (29.761.4 pA, n= 5,
P=0.002) and medium spiny neurons (26.661.7 pA, n= 5,
P=0.01) (Fig. 3). However, again, low concentrations of GHB
(10 mM), induced no significant current. (VB: 20.160.2 pA,
n = 5, P=0.5; medium spiny neurons: 20.260.4, n= 5, P=0.6)
(Fig. 3).
To confirm that the lack of action of GHB was not due to some
alteration in the concentration dependence between expression
systems and brain slices, we applied GHB at 3 mM while using a
K-MeSO4 based pipette solution with [Cl]i = 5 mM and voltage
clamped the cells at 250 mV. Under these conditions chloride
currents have a calculated reversal potential of 284 mV and
hence would be expected to produce outward currents. When
GHB (3 mM) was applied to VB thalamic neurons, a significant
outward current was produced (94624 pA; n= 7, P=0.008)
(Fig. 4A). However, this current was solely the result of GHB
activating GABAB receptors, as the outward current was abolished
by co-application of the GABAB antagonist CGP 55845 (1 mM)
(065 pA; n= 7, P=0.96). Likewise, in dentate gyrus granule cells,
Figure 2. GHB has no effect on synaptic GABAA receptors. A1, Representative average mIPSC from a VB thalamic neuron before and after
application of GHB. A2, GHB has no effect on the decay time constants of averaged mIPSCs in VB neurons. A3, Distribution of mIPSCs amplitude
across 9 cells, showing no effect of GHB. B1, Representative average mIPSC from a dentate gyrus (DG) granule cell before and after application of
GHB. B2, GHB has no effect on the decay time constants of averaged mIPSCs in dentate gyrus granule cells. B3, Distribution of mIPSCs amplitude
across 6 cells, showing no effect of GHB. C1, Representative average mIPSC from a striatal medium spiny neuron (MSN) before and after application of
GHB. C2, GHB has no effect on the decay time constants of averaged mIPSCs in medium spiny neurons. C3, Distribution of mIPSCs amplitude across
11 cells, showing no effect of GHB.
doi:10.1371/journal.pone.0079062.g002
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GHB (3 mM) produced a significant outward current that was
completely blocked by CGP 55845 (1 mM) (GHB: 4963 pA,
CGP: 262 pA; n= 6, P,0.0001, P=0.4 respectively) (Fig. 4B).
However, in medium spiny neurons, GHB (3 mM) did not
produce any significant current and CGP 55845 (1 mM) had no
further effect (GHB 362 pA, CGP: 262 pA; n= 6, P=0.2,
P=0.4 respectively) (Fig. 4C). This is in line with previous reports
that the GABAB receptor has no post-synaptic effect on medium
spiny neurons [33].
Discussion
It is well established that GHB is an agonist at GABAB
receptors, however, evidence suggests that it also has some
behavioural effects via another site: the GHB receptor. For
instance, NCS-382, the GHB receptor antagonist has been
demonstrated to block GHB-induced hypolocomotion and ataxia
[9]. A recent study by Absalom et al., (2012) suggests that the
GHB receptor is in fact the a4b1d GABAA receptor, and that
GHB is a direct agonist at these receptors [20]. We recorded from
three cell types that express the mRNA for these subunits, and
express a GABAA mediated current with the pharmacological hall
marks of a4bxd receptors: VB thalamic neurons, dentate gyrus
granule cells and striatal MSNs [23,34–38]. In these cell types we
found no evidence that 10 mM GHB affected synaptic or
extrasynaptic GABAA receptors, nor that it evoked a measureable
current when applied to nucleated patches. Furthermore while
3 mM GHB activated GABAB receptors, there was no indication
that it activated any GABAA receptors.
There are at least three potential explanations for the
differences seen between our results and those of Absolom et al.,
(2012). The first is that their results are due to an artefact of the
heterologous expression system used. This seems unlikely as their
autoradiographic experiments show clear GHB and NCS-382
binding that is reduced in a42/2 mice. The second possibility is
that the a4b1d receptor is expressed by only a few cells in the
regions we sampled from. This is always an issue with single cell
experiments. However, if the cells are sufficiently rare that in a
sample of 77 neurons/patches to which GHB was applied, not a
single sign of a GABAA receptor mediated current was seen, it
calls into question the functional significance of this GHB at this
receptor combination. The other explanation is that the regions
we studied do not express a4b1d GABAA receptors at all, but
instead express a4b2/3d receptors. The pharmacological and
knockout evidence makes it clear that VB thalamic neurons,
dentate gyrus granule cells and striatal medium spiny neurons
express a4bxd GABAA receptors [24,25,36–38], however, which b
subunit is expressed with these receptors is less clear. The fact that
Figure 3. Puff application of GHB has no effect on nucleated patches pulled from VB thalamocortical cells, or medium spiny
neurons. A1, Example traces showing the effect of 2 second puff applications of GHB (10 mM) and THIP (1 mM) to nucleated patches of
thalamocortical VB neurons. A2, Group results showing the magnitude of the effect of THIP and GHB in VB neurons. B1, Example trace showing the
effect of 2 second puff application of GHB (10 mM) and THIP (1 mM) to nucleated patches of medium spiny neurons. A2, Group results showing the
magnitude of the effect of THIP and GHB in medium spiny neurons.
doi:10.1371/journal.pone.0079062.g003
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the b2/3 selective compound etomidate enhances the tonic
current in VB neurons shows that the tonic current is in part
mediated by b2/3 containing GABAA receptors [39]. However,
given that the tonic current of b22/2 mice is only reduced by
approximately 50%, it indicates that the tonic current in these
neurons is partially produced by b1 and/or b3 containing
receptors [39]. Importantly, the tonic current from mice with
the etomidate insensitive b2N265S mutation is still enhanced by
etomidate, showing that the tonic current is in part mediated by b3
receptors, however it is unclear whether b1 containing receptors
Figure 4. High concentrations of GHB can induce an inward current that is completely abolished by the GABAB antagonist GCP
55845. A1, Representative recording from a VB thalamic neuron showing the inward current induced by 3 mM GHB, and its blockade by CGP 55845
revealing no residual current. A2, Group results showing the current induced by GHB and its complete blockade by CGP 55845. B1, Representative
recording from a dentate gyrus (DG) granule cells showing the inward current induced by 3 mM GHB, and its blockade by CGP 55845 revealing no
residual current. B2, Group results showing the current induced by GHB and its complete blockade by CGP 55845. C1, Representative recording from
a striatal medium spiny neuron (MSN) the complete lack of response to 3 mM GHB and CGP 5584. C2, Group results showing the lack of effect of GHB
or CGP 55845.
doi:10.1371/journal.pone.0079062.g004
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also mediated part of the tonic current. At least at a6bxc2
receptors, etomidate has very similar modulator properties at b2
and b3 containing receptors [40]. However, in VB neurons from
b22/2 mice, etomidate enhances the tonic current significantly
less, suggesting that some of the tonic current is mediated by b1
containing receptors (though this could be due to a compensatory
upregulation of b1 subunits in response to a loss of b2 subunits)
[39]. In the dentate gyrus an identical approach shows that
neurons from b22/2 mice have a halved tonic current, and that
the tonic currents from b2N265S mice are still partially sensitive to
etomidate, showing the presence of b3 containing extrasynaptic
receptors. Again, the magnitude of the etomidate-induced
enhancement of the tonic current in b22/2 mice suggests the
presence of some b1 containing receptors [41] Furthermore, a
recent study has shown that protein kinase A (PKA) inhibits the
current mediated by extrasynaptic receptors in VB thalamic
neurons [42]. As PKA has been shown to inhibit b1 containing
receptors, while having no effect on those containing b2 and
enhancing b3 containing receptors, this indicates that VB thalamic
neurons contain a significant amount of b1 containing GABAA
receptors, at least at extrasynaptic sites [43,44]. While these results
make it hard to say conclusively which b subunits are expressed at
the extrasynaptic GABAA receptors in these nuclei, it is worth
noting that Absalom et al., (2012) did show clear gabazine
sensitive [3H]NCS-382 binding in the thalamus, dentate gyrus
and striatum, showing that this site does appear to be present in
the brain regions we studied [20].
While our results show no indication that GHB is a direct
agonist of GABAA receptors, it is worth noting that GHB can
potentiate extrasynaptic receptors, however, we have shown that
this is through an indirect mechanism, relying of GABAB receptors
[35,42]. These results showed that activation of the GABAB
receptor leads to a dephosphorylation of presumably a4b1d
containing receptors and a subsequent potentiation of extrasynap-
tic GABAA currents [42]. However, we cannot use these results to
explain the findings of Absalom et al., (2012) [20].
Given that we could see no indication that GHB was an agonist
of GABAA receptors in VB thalamus neurons, dentate gyrus
granule cells or striatal medium spiny neurons, we are left with
three possibilities, 1) that GHB is not an agonist of a4b1d native
receptors, 2) the receptors are expressed in rare cell populations or
3) that these receptors do not exist in these brain regions. We
cannot rule out any of these option. However, if these receptors do
exist in any significant number, we feel it is unlikely that GHB is as
potent an agonist as suggested by Absolom et al., (2012) [20]. This
is due to the fact that all known reports of a behavioural effect due
to GHB dosing require doses of $100 mg/kg, even those reported
to be antagonised NCS-382 [e.g. 3,9,10]. Seeing as doses of
120 mg/kg (I.V in the cat) produce cerebrospinal fluid (CSF)
concentrations of ,2.5 mM, and even endogenous GHB is found
in the CSF at 100 nM (and .1 mM in bulk tissue), it would seem
that the a4b1d would be being activated at near its EC50 basally,
and would be well past saturation before a behaviourally relevant
concentration is reached [45,31,30]. Whether the effect of low
concentrations of GHB on a4b1d receptors is an artefact of the
heterologous expression system, or simply that a4b1d is not found
in the CNS, our results call into question the relevance of the
proposed direct action of GHB on extrasynaptic GABAA receptors
in native tissue.
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